1. Introduction {#sec1-ijms-19-00761}
===============

Wound healing is the essential process to protect the body from further environmental insults after trauma. It is segmented into discrete phases, namely hemostasis, inflammation, proliferation, and remodeling \[[@B1-ijms-19-00761]\]. The inflammatory phase is central in steering healing into either a physiological or a pathological course. This phase is characterized by swift neutrophil influx, followed by later immigration of macrophage \[[@B2-ijms-19-00761]\]. To oppose any invading pathogen expected during tissue injury, a pro-inflammatory milieu dominates that is controlled via chemokines and cytokines \[[@B3-ijms-19-00761]\]. Once these pro-inflammatory setting is lacking sustained stimuli, e.g., due to clearance of bacteria, the mediator profile switches \[[@B4-ijms-19-00761]\]. This causes macrophage re-programming towards an anti-inflammatory, pro-wound healing phenotype \[[@B5-ijms-19-00761]\]. As consequence, keratinocyte and fibroblast influx is promoted, and the wound is sealed and remodeled \[[@B6-ijms-19-00761]\].

Non-healing wounds and ulcers are a major burden for patients and western health care systems alike \[[@B7-ijms-19-00761]\]. Molecularly, these wounds do not progress from the pro to the anti-inflammatory phase but stay in between them \[[@B8-ijms-19-00761]\]. This is often coined "chronic" inflammation; i.e., an ongoing inflammatory phase that is attenuated but not resolved \[[@B9-ijms-19-00761]\]. Chronic wounds are thought to be a consequences of either endogenous factors, such as impaired angiogenesis as seen in diabetic patients, or exogenous factors, such as excessive presence of pathogens \[[@B10-ijms-19-00761]\]. In both cases, the wounds display distinct molecular signatures that are either a consequence or the driver of impaired healing \[[@B11-ijms-19-00761],[@B12-ijms-19-00761],[@B13-ijms-19-00761]\]. To differentiate between features of pathological healing being hen or egg, studies on physiological healing greatly enhance the understanding of this highly complex, multi-facetted process \[[@B14-ijms-19-00761]\]. Especially wound fluid has added to the understanding of healing in the past as it contains material from wound-resident cell such as neutrophils \[[@B15-ijms-19-00761]\].

Neutrophils are the dominant cell type in inflammation as well as chronic wounds \[[@B16-ijms-19-00761]\]. These cells are armed with an arsenal of molecules toxic to pathogens and host cells \[[@B17-ijms-19-00761]\]. This includes the release of a number of enzymes with proteolytic and antimicrobial activity \[[@B18-ijms-19-00761]\]. Neutrophils are also capable of release extracellular traps; antimicrobial DNA decorated with inflammatory enzymes \[[@B19-ijms-19-00761]\]. Neutrophils have been observed to produce and release microparticles \[[@B20-ijms-19-00761]\]; small double-membraned vesicles encapsulating signaling and enzymatic proteins, small molecules, and messenger RNA \[[@B21-ijms-19-00761]\]. Importantly, the granulocytes are major producers of reactive oxygen and nitrogen species (ROS/RNS) \[[@B22-ijms-19-00761]\]. Two major enzymes are superoxide-producing Flavin reductase (NADPH) oxidases and hypochlorous acid-generating myeloperoxidase \[[@B23-ijms-19-00761]\]. Acute wound healing in rats has been observed to contain peak concentrations of 200 µM hydrogen peroxide \[[@B24-ijms-19-00761]\]. This molecule is a major chemoattractant for neutrophils \[[@B25-ijms-19-00761]\]. Consequently, it has long been proposed that wound healing is subject to redox control \[[@B26-ijms-19-00761]\].

The aim of this study was to investigate wound exudates of acutely healing wounds on a cellular and protein level. Finding and confirming that large parts of cells in exudates are neutrophils as shown by surface marker profiles, we also identified neutrophil-derived small particles in our samples. Adding to and largely confirming a previous study \[[@B27-ijms-19-00761]\], proteomic analysis of protein targets as well as their post-translational modifications (PTMs) revealed a in part unreported signature in the exudates of healing wounds.

2. Results {#sec2-ijms-19-00761}
==========

2.1. Proteomics of Wound Exudates {#sec2dot1-ijms-19-00761}
---------------------------------

Identified proteins from wounds identified in patients ([Table 1](#ijms-19-00761-t001){ref-type="table"}) were classified based on their function, compartment, and biological process ([Figure 1](#ijms-19-00761-f001){ref-type="fig"}). Alternatively, proteins were sorted based on their role in wound healing, e.g., activation of anti-oxidant factors such as oxidoreductases ([Table 2](#ijms-19-00761-t002){ref-type="table"}), immune modulators, chaperone and heat shock proteins ([Table 3](#ijms-19-00761-t003){ref-type="table"}), neutrophil and leukocytes associated factors ([Table 4](#ijms-19-00761-t004){ref-type="table"}), extracellular matrix proteins ([Table 5](#ijms-19-00761-t005){ref-type="table"}) as well as proteinases and peptidases ([Table 6](#ijms-19-00761-t006){ref-type="table"}). An overview of the relative abundances of these proteins is given in [Figure 2](#ijms-19-00761-f002){ref-type="fig"}.

### 2.1.1. Oxidoreductases {#sec2dot1dot1-ijms-19-00761}

Anti-oxidative stress factors counteract oxidative stress present during wound healing. A large set of proteins belonging to anti-oxidant down-stream signaling response such as catalase (CAT) several peroxidases (PRDX1, 2, 6, MPO), and superoxide dismutase (SOD1) \[[@B28-ijms-19-00761],[@B29-ijms-19-00761],[@B30-ijms-19-00761]\] was identified in wound fluids. Oxidoreductases such as cytochrome C oxidase (MT-COX2), the terminal enzyme in the mitochondrial respiratory chain, catalyze the reduction of oxygen for energy recovery \[[@B31-ijms-19-00761]\] and its presence in wound fluids prevents an excessive inflammatory response \[[@B32-ijms-19-00761]\]. [l]{.smallcaps}-lactate dehydrogenase (LDHB), a marker of tissue destructive microenvironment and hemolysis \[[@B33-ijms-19-00761]\], was also identified. Dehydrogenases represents an additionally protein class of oxidoreductases, of which malate dehydrogenase (MDH2), and flavin reductase (NADPH; BLVRB) was detected ([Table 2](#ijms-19-00761-t002){ref-type="table"} and [Figure 2](#ijms-19-00761-f002){ref-type="fig"}). These data indicate the presence of enzymes of the anti-oxidative defense system in wound fluids obtained from the traumatic acute wounds.

### 2.1.2. Immune Modulators, Chaperones, and Heat Shock Proteins {#sec2dot1dot2-ijms-19-00761}

Several members of the complement factor family ([Table A1](#ijms-19-00761-t0A1){ref-type="table"}) as well as numerous members of the S100A protein family (e.g., S100A4, 6, 8, 9, 11, S100P) were found in the exudates of traumatic wounds ([Table 3](#ijms-19-00761-t003){ref-type="table"} and [Figure 2](#ijms-19-00761-f002){ref-type="fig"}). Chaperone and heat shock proteins (HSP) are inducible stress proteins promoting wound closure by recruitment of dermal fibroblasts in late stages of wound repair \[[@B34-ijms-19-00761]\]. We identified several HSP family members such as endoplasmin (HSP90B1), HSPA1A, HSPB, and HSP8. Moreover, calreticulin (CALR) and different 14-3-3 protein family members were detected in wound fluids ([Table 3](#ijms-19-00761-t003){ref-type="table"}, middle part). The detection of α2-macroglobulin (A2M), which is mainly synthesized by macrophages and fibroblasts, suggest a functional inhibition of an enormous variety of proteinases. \[[@B35-ijms-19-00761]\] Additionally, nicotinamide phosphoribosyltransferase (NAMPT) enables NAD^+^ biosynthesis, and functions as cytokine that promotes B cell maturation as well as inhibition of neutrophil apoptosis \[[@B36-ijms-19-00761]\]. Two members of the Guanosine-5′-triphosphate (GDP)-dissociation inhibitors of Rho proteins (ARHGD1/2) were identified regulating GDP/Guanosine-5′-triphosphate (GTP) exchange and activating oxygen superoxide-generating NADPH oxidase of phagocytes \[[@B37-ijms-19-00761]\]. Based on our proteomic approach, the abundance of several annexin family members (ANX1, 2, 3, 4, 5, 11) was further shown ([Table 3](#ijms-19-00761-t003){ref-type="table"}, last part) confirming previous results provided by novel proteomic methodology \[[@B27-ijms-19-00761]\].

### 2.1.3. Neutrophil and Leukocytes Associated Factors {#sec2dot1dot3-ijms-19-00761}

Numerous immune modulators such as lactotransferin (LTF), azurodicin (AZU1), bactericidal permeability-increasing protein (BPI) and lipocalin (LCN2) were identified ([Table 4](#ijms-19-00761-t004){ref-type="table"} and [Figure 2](#ijms-19-00761-f002){ref-type="fig"}), which are often associated with host defense against a broad range of microorganisms, immune response, anti-inflammatory activity and regulation of cellular growth as well as differentiation. A balance of the presence of neutrophil elastase (ELANE), inhibitors of leukocyte elastase (SERPINB1) and cathepsin G and Z (CTSG/Z) were found suggesting a strong regulation of a variety of proteolytic events important to tissue repair \[[@B27-ijms-19-00761]\]. Further results also indicate an increased existence of protease inhibitors in the healing wound fluid ([Table A2](#ijms-19-00761-t0A2){ref-type="table"}). Additionally, a proteolysis-activated plasminogen (PLG) and an antimicrobial enzyme lysozyme (LYZ) were detected in wound exudates indicating an activated stage of proteases in cellular processes such as wound healing and of innate immune system, respectively. Moreover, the anti-inflammatory transforming growth factor B1 (TGFβ1) activates macrophages and regulates a variety of cellular functions including cell proliferation, differentiation, and apoptosis, which are important during the different stages of wound healing.

### 2.1.4. Extracellular Matrix Proteins {#sec2dot1dot4-ijms-19-00761}

The extracellular matrix (ECM) is predominantly formed by collagen and is an essential component of the skin among fibroblasts, keratinocytes, endothelial cells, and immune cells \[[@B38-ijms-19-00761]\]. Sixteen ECM molecules were obtained including several collagens (COL1A1, 2, 5, 6), fibrinogens (FGA, FGB, FGG) and oligomeric lectins consisting of both, collagen-like stretches and fibrinogen (e.g., FCN1) \[[@B39-ijms-19-00761]\]. All proteins may function as hallmarks and biomarkers of newly generated granulation tissue and provisional wound matrix ([Table 5](#ijms-19-00761-t005){ref-type="table"} and [Figure 2](#ijms-19-00761-f002){ref-type="fig"}). Furthermore, lumican (LUM), vitronectin (VTN), olfactomedin-4 (OLFM4), and cartilage oligomeric matrix protein 2 (COMP2) were identified in wound fluids regulating tissue repair, collagen fibril organization and formation \[[@B40-ijms-19-00761]\]. Galectin 3 (LGALS3) and the vasodilator-stimulated phosphoprotein (VASP), which were also found in wound fluids, are recruit to cell-cell junctions at the wound edge \[[@B41-ijms-19-00761]\].

### 2.1.5. Proteinases {#sec2dot1dot5-ijms-19-00761}

Ubiquitous intracellular peptidases belonging to the proteasome (7 proteins: PSMAs/PSMBs; [Table 6](#ijms-19-00761-t006){ref-type="table"} and [Figure 2](#ijms-19-00761-f002){ref-type="fig"}) and caspase 3 (CASP3), indicate active inflammatory cellular processes \[[@B42-ijms-19-00761]\] and show that cellular cytoplasmic fractions are present in the collected samples. The serine protease Cathepsin G (CATG) plays an integral part in immune response and inflammatory processes, being associated to NETs \[[@B18-ijms-19-00761]\]. Aminopeptidase N (AMPN) is a peptidase with broad specificity, playing a role in MHCII presented antigen cleavage and in angiogenesis \[[@B43-ijms-19-00761]\]. Apolipoprotein (APOA) inhibiting tissue-type plasminogen activator 1 and matrix metalloprotease 9 (MMP9) indicate a controlled ECM modulation and leukocyte migration \[[@B44-ijms-19-00761]\]. Moreover, presence of prothrombin indicates the presence of blood in the wound bed \[[@B45-ijms-19-00761]\].

### 2.1.6. Post-Translational Modifications {#sec2dot1dot6-ijms-19-00761}

Besides general annotation of proteins by mass spectrometry (MS), several chemical modifications were searched for in the generated data sets ([Table A3](#ijms-19-00761-t0A3){ref-type="table"}). Numerous cysteine oxidations were observed: both cysteine sulfenic acid and, predominantly, cysteine sulfonic acid. Most single oxidations were found at methionines forming methionine sulfoxide, as cysteine sulfenic acid is both partially reduced by Dithiothreitol (DTT) and instable during ionization. In total, oxidative modifications were the most common observed changes compared to nitrosative modifications. Most nitrosative modifications were found to be tyrosine nitration as well as very low amounts of nitrosated cysteine. Additionally, carbamidomethylations were introduced during the reduction/alkylation work step during sample preparation.

2.2. Manually Obtained Wound Material {#sec2dot2-ijms-19-00761}
-------------------------------------

After the wound sponge was removed, from which the material for mass spectrometry analysis was obtained, a swab was used to obtain additional wound material. From this, pelleted material as well as supernatant were analyzed. Within the pelleted material, the percentage ([Figure 3](#ijms-19-00761-f003){ref-type="fig"}a) of neutrophils (CD16^+^/CD66^+^) and non-neutrophils (CD16^−^/CD66^−^; mostly lymphocytes) among CD45^+^/DAPI^+^ cells was calculated ([Figure 3](#ijms-19-00761-f003){ref-type="fig"}b). There was about four times more neutrophils than non-neutrophils in the pelleted fraction. Neutrophils exposed to stimulating agents such as wound-resident bacteria are known to generate sticky DNA decorated with antimicrobial proteins such as myeloperoxidase (MPO), so-called neutrophil extracellular traps (NETs) \[[@B19-ijms-19-00761]\]. To identify such structures, the pelleted material was stained for DNA (DAPI; [Figure 3](#ijms-19-00761-f003){ref-type="fig"}c), and MPO ([Figure 3](#ijms-19-00761-f003){ref-type="fig"}d). A substantial percentage of double-positive events among all acquired events was identified by flow cytometry in the pelleted fraction ([Figure 3](#ijms-19-00761-f003){ref-type="fig"}e). Another feature of eukaryotic cells in general and neutrophils in particular is the release of small vesicles carrying cargo protein and RNA for cell-cell communication and modulation of the tissue microenvironment, so-called microparticles \[[@B46-ijms-19-00761]\]. To identify these small (\<1 µm) membraned vesicles in the supernatant of wound material, we applied a stringent flow cytometry gating and staining strategy, tightly discriminating for doublets in the forward scatter ([Figure 4](#ijms-19-00761-f004){ref-type="fig"}a), side scatter ([Figure 4](#ijms-19-00761-f004){ref-type="fig"}b), and size exclusion (\<1 µm; [Figure 4](#ijms-19-00761-f004){ref-type="fig"}c) using flow beads. Applying a membrane-stain, we were able to discriminate non-membraned events from microparticles ([Figure 4](#ijms-19-00761-f004){ref-type="fig"}d). Among microparticles, we tested for the percentage of neutrophil-derived CD15^+^ particles ([Figure 4](#ijms-19-00761-f004){ref-type="fig"}e) that were markedly present in the wound material supernatants ([Figure 4](#ijms-19-00761-f004){ref-type="fig"}f). As DNA^+^/MPO^+^ events were identified in the pelleted fraction ([Figure 3](#ijms-19-00761-f003){ref-type="fig"}d), we assayed for DNA ([Figure 4](#ijms-19-00761-f004){ref-type="fig"}g) and oxidants ([Figure 4](#ijms-19-00761-f004){ref-type="fig"}h) in the supernatant as well and found both to be increased.

3. Discussion {#sec3-ijms-19-00761}
=============

This study was conducted to better understand the proteomic signature paralleling physiological wound healing. While previous studies have identified numerous targets important in this process \[[@B47-ijms-19-00761],[@B48-ijms-19-00761],[@B49-ijms-19-00761],[@B50-ijms-19-00761]\], we also identified so far less reported targets as potential biomarkers that contribute to cell growth, inhibit excessive inflammation, and support matrix as well as granulation tissue formation in normal skin repair. Our findings were complemented by data analysis of protein post-translational modifications and immune-focused analysis of wound exudates by flow cytometry.

Reactive oxygen species (ROS) and wound oxygenation are crucial processes in wound repair, and the oxygen-dependent redox-sensitive signaling represent an integral component of the healing cascade \[[@B51-ijms-19-00761]\]. In wound healing, the initiating and activating of ROS-dependent signaling cascades that promote cellular responses are indispensable. We found indirect evidence of ROS in wound fluids and especially neutrophil-derived oxidants were reported to be crucial in the resolution of inflammation \[[@B52-ijms-19-00761]\]. ROS mainly arise from metabolism via the mitochondrial electron transport chain \[[@B53-ijms-19-00761]\] and a number of oxidases in phagocytes \[[@B54-ijms-19-00761]\]. By proteomics, we identified neutrophil myeloperoxidase (MPO), a producer of potent hypochlorous acid \[[@B55-ijms-19-00761]\]. By flow cytometry, we confirmed the presence of MPO not only in neutrophils from wounds but also on fragments that co-stained for DNA, suggesting the presence of neutrophil extracellular traps (NETs) in wound fluids. These sticky microbicidal DNA-extrusion are only poorly described in wound healing, despite the well-reported abundance of neutrophils in wounds \[[@B10-ijms-19-00761]\]. NET formation is redox-regulated via MPO \[[@B56-ijms-19-00761]\], and NETs form in response to microorganisms \[[@B57-ijms-19-00761]\] and oxidants \[[@B58-ijms-19-00761]\]. NETs were reported to be detrimental in diabetic foot healing \[[@B59-ijms-19-00761]\], can be counteracted in wounds via DNAse treatment \[[@B60-ijms-19-00761]\], and are potent ROS producers themselves \[[@B61-ijms-19-00761],[@B62-ijms-19-00761],[@B63-ijms-19-00761]\]. ROS can be used as a signal for cell proliferation in which oxidoreductases are involved by regulating the redox state of proteins \[[@B64-ijms-19-00761]\]. Among them, we found peroxiredoxins (PRDX1, 2, 6) in wound fluids suggesting a strong control of the wound healing-induced peroxide level \[[@B65-ijms-19-00761]\]. In contrast to our proteomic analysis, PRDX2 was previously detected in exudate obtained from non-healing wounds only \[[@B27-ijms-19-00761]\]. Nevertheless, due to the presence of further oxidoreductases (e.g., SOD1, MT-CO2), acute inflammation is accompanied by metabolic changes and a suppression of mitochondrial respiration. Thus, significant alterations in the anti-oxidant profile accompanied by the presence of an arachidonate 5-lipoxygenase-activating protein (ALOX5AP), a lipid mediator of inflammation \[[@B66-ijms-19-00761]\], and numerous other apolipoproteins ([Table A2](#ijms-19-00761-t0A2){ref-type="table"}) may be contributory to healing of traumatic wounds. It was shown in animal studies that re-epithelialization during wound healing was impaired in apolipoprotein (APO) E deficient mice suggesting a beneficial effect of pro-atherogenic lipoproteins on skin fibroblasts and granulation tissue formation, and a direct effect of APOE on wound healing \[[@B67-ijms-19-00761]\]. Next to ALOX5AP as immune-modulator \[[@B68-ijms-19-00761]\], several other factors of inflammation (e.g., ARHGD1/2, NAMPT, etc.) were detected in wound fluids. GDP-dissociation inhibitors of Rho proteins activates NAPDH oxidase (a direct cellular response to redox state) whereas a phosphoribosyltransferase (NAMPT), also known as a pre-B-cell colony enhancing factor 1, enables NAD^+^ biosynthesis. NAMPT functions as cytokine that promotes B cell maturation as well as inhibition of neutrophil apoptosis \[[@B36-ijms-19-00761]\]. Strong immune modulators and clinical targets in hampered wound healing are chemokines and cytokines \[[@B69-ijms-19-00761],[@B70-ijms-19-00761],[@B71-ijms-19-00761]\]. Despite their undeniable presence in acute wound healing as demonstrated a previous cohort \[[@B72-ijms-19-00761]\], the limit of detection may be too low for detection via mass spectrometry or alternative approach such as targeted proteomics are potentially more suitable for their discovery.

A neutrophil proteomic signature was identified in wound fluids. Neutrophil elastase (ELANE) and cathepsin G (CTSG) are major components of neutrophil granules and participate in digestions of phagocytized microorganisms \[[@B73-ijms-19-00761]\]. ELANE was one of the most abundant neutrophil proteins, and is essential in regulating microbial growth in wounds \[[@B74-ijms-19-00761]\]. The presence of numerous proteins such as lactotransferin (LTF) or azurocidin 1 (AZU1) could be also shown in wound fluids of traumatic wounds in contrast to recently published proteomic studies \[[@B27-ijms-19-00761]\] suggesting an effective impact of antimicrobial acting proteins on physiological wound healing. LTF had the highest abundance among all neutrophil-associated proteins. LTF aids in binding of nucleic acid and iron with a major role in destabilization of microbial membranes \[[@B75-ijms-19-00761]\]. With all wounds ultimately healing properly indicating at least no pathological microbial burden after surgery, we can only speculate that the main role of LTF may not have been antimicrobial one. The second most abundant neutrophil-associated protein was SERPINB1, which acts as ELANE (also among most abundant proteins) inhibitor and is released by neutrophils themselves \[[@B76-ijms-19-00761]\], underlining inflammatory fine-tuning in neutrophil products. Along similar lines, neutrophil gelatinase-associated lipocalin proteins (LCN) are involved in inflammation and detoxification processes caused by immune system activation in humans. Liver-derived PLG is known to be a critical regulator of cutaneous wound healing \[[@B77-ijms-19-00761]\], and neutrophils are major cells targeting PLG \[[@B78-ijms-19-00761]\]. We also identified BPI in highly abundant levels similar to a previous study where it was mildly associated with infection \[[@B79-ijms-19-00761]\]. It is a potent protein antibiotic active against Gram-negative bacteria by binding to the lipopolysaccharide \[[@B80-ijms-19-00761]\].

We identified a broad spectrum of extracellular matrix (ECM) proteins. Modulating the process of wound healing, ECM proteins bind numerous growth factors like TGF and release they after degradation of ECM proteins by proteolytic enzymes \[[@B81-ijms-19-00761]\]. Not only the group members of collagen family is known to be strong associated with physiological wound healing but also the expression of fibrinogens and matrix metalloproteinases. They function as markers of formation of granulation tissue, re-epithelialization and ECM remodeling in dermal repair processes \[[@B81-ijms-19-00761]\]. Proteins such as vitronectin, lumican, olfactomedin-4, a cartilage oligomeric matrix protein 2, and other glycoproteins ([Table A2](#ijms-19-00761-t0A2){ref-type="table"}) are basic components of the newly formed provisional matrix at early wound healing stages and reflect---together with the presence of collagens---a physiological healing response. α2-macroglobulin (A2M), an anti-protease inhibiting proteinase, binds to and removes the active forms of gelatinases (e.g., MMP2 or 9) from the circulation via scavenger receptors on the phagocytes. A2M further inhibits plasminogen (PLG) and fibrolysis \[[@B82-ijms-19-00761]\]. The vasodilator-stimulated phosphoprotein (VASP) and galectin 3 (LGALS3) play important roles in cell-cell adhesion and wound closure as well as in cell-matrix interactions, macrophage activation, and angiogenesis \[[@B83-ijms-19-00761]\]. Moreover, calreticulin (CALR) and CD59 were identified, both present on human neutrophils \[[@B84-ijms-19-00761]\]. In addition other 14-3-3 protein family members were detected in wound fluids, which mainly controls renewal of epithelium \[[@B85-ijms-19-00761]\], and stimulation of epithelial cell migration after wounding \[[@B86-ijms-19-00761]\]. Calcium binding proteins such as S100 factors are regulators of calcium homeostasis, inflammation, proliferation, cell cycle progress, and migration. They interact with a variety of target proteins on monocytes/macrophages, neutrophils, and lymphocytes \[[@B87-ijms-19-00761]\]. S100A1 protein has been identified as novel regulator of endothelial angiogenesis suggestive to reflect pro-angiogenetic properties of this protein necessary for wound healing \[[@B88-ijms-19-00761]\]. S100A4 presence is associated with processes of increased cell migration and transcriptional regulation of matrix metalloproteinases, e.g., MMP9, which was also found in our study. S100A6 has a role in cell response to different stressors such as heat shock proteins (e.g., HSP90). Among the S100 proteins, S100A8 and 9 are induced by pro-inflammatory stimuli in macrophages, dendritic cells, epithelial cells, and fibroblasts \[[@B89-ijms-19-00761]\]. Both proteins were also found in wound exudates obtained from normal healing \[[@B27-ijms-19-00761]\] corroborating our results. Additionally, it was recently shown that S100A8/9 overexpression in HaCaT keratinocytes increases NADPH oxidase activity and enhances ROS levels \[[@B87-ijms-19-00761]\] underlining the concept of redox regulation during wound healing \[[@B64-ijms-19-00761]\]. S100P reduces focal cell adhesion \[[@B90-ijms-19-00761]\] emphasizing a support of cell migration. Moreover, the presence of S100A11 indicates a stimulation of keratinocyte cell growth by enhancing the level of several growth factors \[[@B91-ijms-19-00761]\] and we have previously shown a redox regulation of several S100 proteins in human keratinocytes \[[@B92-ijms-19-00761]\]. Based on our proteomic approach, the abundance of several annexins (ANX1, 2, 3, 4, 5, 11) was further demonstrated, which are linked to fibrinolysis, coagulation, inflammation and apoptosis \[[@B93-ijms-19-00761]\], and to trafficking and organization of vesicles, exocytosis, endocytosis, calcium ion channel formation \[[@B94-ijms-19-00761]\]. Trafficking and release of small vesicles, so-called microparticles, is important in neutrophil biology \[[@B95-ijms-19-00761]\]. Neutrophil microparticles stain positive for CD15 \[[@B96-ijms-19-00761]\]. Proteomic analysis of neutrophil-derived microparticles \[[@B97-ijms-19-00761]\] was highly congruent with many targets found in wound fluids, among them annexin A1, A4, A5, and A11, AZU1, ELANE, MPO, BPI, B2M, CALR, CTSG, CTSZ, FCN-1, GRB2, LTF, LYZ, HSP70, HSP71, HSP90, MMP9, PRTN3, PRDX1, S100A9, and others, underlining the strong neutrophil signature in acute wound exudates. On annexins, Eming and colleagues validated its ability remove apoptotic cells to consolidate them as biomarkers to predict healing of traumatic, acute wounds \[[@B27-ijms-19-00761]\].

Regarding chemical modifications, it is well known that oxidative as well as nitrosative modifications have a strong impact on several body functions, e.g., the immune response. Modifications observed by MS are known to be involved in various pathways in inflammation and wound healing. Methionine sulfoxide is the most common modification found by MS besides carbamidomethylation. It is described to attenuate the functions of NFκB and NFTA as well as indirectly influencing the T-cell receptor/CD3 signal transduction pathway \[[@B98-ijms-19-00761]\], indicating its role in immune cell recruitment. In addition, oxidized cysteine residues were observed as the second most occurring modification. Cysteines, and their specific redox state, are key in recruiting leukocytes to freshly wounded tissue, e.g., by the Scr family kinase Lyn \[[@B99-ijms-19-00761]\]. Both modifications can be introduced by hydroxyl radicals as well as hydroxyl radical-forming species, such as hydrogen peroxide, which is also known to be critical affecter of wound healing and immune cell recruitment \[[@B25-ijms-19-00761],[@B100-ijms-19-00761],[@B101-ijms-19-00761]\]. Besides oxidative modification, the formation of nitrotyrosine was observed. Nitrotyrosine is widely regarded as a marker for inflammation \[[@B102-ijms-19-00761]\], and nitrosated peptides can modulate the immune response when presented at MHC complexes \[[@B103-ijms-19-00761]\]. Proteins incorporating nitrotyrosine are discussed to be formed by the impact of the reactive nitrogen species peroxynitrite \[[@B104-ijms-19-00761]\]. Finally, a protein-*S*-nitrosocysteine was only observed in one instance. This specific PTM is supposed to be physiologically highly active in both innate and adaptive immune system regulation, e.g., by modulating toll-like receptor activity \[[@B105-ijms-19-00761]\]. However, the S-NO moiety is comparably instable, and the occurrence in the wound fluids is likely being underestimated in mass spectrometric approaches. The various oxidative and nitrosative modifications observed are in good agreement with modifications typically associated with the immune response required to trigger wound healing. The redox-based signaling in immune system regulation both by RONS themselves as well as their resulting chemical modifications might be a prime target for clinical application \[[@B106-ijms-19-00761]\]. A controlled regulation of the immune response might allow for faster wound healing with reduced chance of complications, e.g., the formation of chronic wounds. In this regard, first studies using topical applications of *S*-nitrosocysteine as a donor of the second messenger NO seem to be well-received and have the potential to enhance wound healing \[[@B107-ijms-19-00761]\].

This study had limitations. Regarding the quantification of neutrophils from wound exudates, dead cells were excluded from the analysis only through forward scatter/side scatter profiles but not fluorescence dyes such as propidium iodide because immediate assaying after surgery was not always possible. Moreover, we did not compare surgical wound material with other wound types, such as chronic ulcers or burn wounds, limiting conclusions about potential therapeutic interventions with any of the targets identified. However, there was significant overlap of proteins identified with a previous study that had compared healing and non-healing wounds \[[@B27-ijms-19-00761]\], validating our experimental approach. Nonetheless, this study is rather descriptive, allowing only speculating about the possible mechanistic role of proteins identified in human wound fluids.

In conclusion, we confidently identified hundreds of proteins present during healing of human wounds. Along with data from flow cytometry, this protein signature revealed a major role of neutrophils and their products in wound healing. Moreover, the proteomic study finding oxidoreductases and oxidative post-translational modifications provided evidence of redox control in wound healing. Both corroborates findings and hypothesis of previous studies but in addition resolves the molecular pattern to an extended degree. Together with future studies, this may help to resolve the central processes in human wound healing in physiology and pathology.

4. Materials and Methods {#sec4-ijms-19-00761}
========================

4.1. Wound Material {#sec4dot1-ijms-19-00761}
-------------------

Wound exudates were collected onsite immediately after sponge removal in the surgical theater as described before \[[@B72-ijms-19-00761]\]. Briefly, two sterile swabs were used to collect material of the wound area. Swabs were rinsed in tubes containing 1 mL of phosphate-buffered saline (PBS) on ice. Tubes were centrifuged, and the supernatant was collected and processed. Cell pellets were fixed with 1% paraformaldehyde until analysis. Wound sponge dressings obtained during surgery were immediately collected into tubes and stored at −80 °C until protein preparation. The sponges are made from polyurethane and are frequently used in vacuum assisted wound therapy. In total, proteins were isolated from 11 patients ([Table 1](#ijms-19-00761-t001){ref-type="table"}). This study was approved by the local Greifswald ethics committee (BB 113/14, 12 January 2015).

4.2. Protein Preparation from Material in Wound Sponge Dressings {#sec4dot2-ijms-19-00761}
----------------------------------------------------------------

A small cube was cut from each dressing with roughly 5 mm edge length and each cube was weighted on a micro scale as swab loading differed strongly between patients. 50 µL RIPA buffer (1 mM EDTA, 0.5 mM EGTA, 1% (*v*/*v*) Triton X-100, 0.1% sodium deoxycholate, 0.1% (*w*/*v*) SDS, 140 mM NaCl, 1 mM PMSF, 10 mM Tris/HCl, pH 8) with protease and phosphatase inhibitors (Roche complete mini) was added to each swab per 10 mg wet weight and samples were incubated for 1 h on ice with periodic vortexing. Afterwards, samples were centrifuged at 4 °C for 1 h to remove cell debris and supernatants were decanted into fresh reagent tubes. Proteins were precipitated with acetone overnight and centrifuged for 1 h at 4 °C. To ease re-suspension of proteins, pellets were re-suspended in 500 mM Tris-HCl (pH 7.4), 10% (*w*/*v*) SDS, 5% (*w*/*v*) β-mercaptoethanol. Afterwards, protein concentrations were measured using a modified Bradford assay (RCDC, Bio-rad, Hercules, CA, USA). As each patient sample was differing strongly, "master" samples were generated by combining 10 µg protein of each sample together. In this way, a more comprehensive overview, which proteins would be present in high abundance in all patients, was possible.

Two master samples were generated independently and 30 µg protein each was loaded onto a precast Tris-Glycerine gel (Bio-rad) in duplicates. Gels were run at 125 V for about 90 min and stained/destained following standard procedures. Lanes containing samples were cut into 10 slices each. From this point on, all reagents and consumables were of LC/MS grade (e.g., LoBind, Eppendorf, Hamburg, Germany) Gel slices were destained using 400 µL washing solution (20 mM NH~4~HCO~3~ in 30% acetonitrile) on a shaker for 15 min. This procedure was repeated with fresh solution until slices were destained. Gel slices were dried in a vacuum centrifuge for about 35 min. Afterwards, proteins in the gel slices were reduced using 50 µL of 10 mM dithiothreitol at 60 °C for 1 h followed by an alkylation step with 50 µL of 50 mM iodoacetamide at 25 °C for 30 min. Afterwards, samples were washed twice with washing solution and supernatant was removed. Gel slices were again dried in a vacuum centrifuge for about 25 min (time adapted independently for each slice) prior to in-gel digestion using trypsin (10 µg/mL, sequencing grade, Promega, Wisconsin-Madison, WI, USA) in a volume adequate to cover the specific gel slices. Digestion was performed for 16 h at 22 °C.

After digestion, peptides were extracted from the gel slices by consecutively using 50 µL of 5% formic acid, 50 µL acetonitrile, and 100 µL acetonitrile. After each solvent addition, samples were toughly vortexted for 15 min, centrifuged for 1 min and supernatants pooled in a fresh reagent tube. Afterwards, the resulting 200 µL were reduced to about 10 µL by vacuum centrifugation and 20 µL of *A. dest.* added. Samples were stored at −80 °C until measurement.

4.3. Mass Spectrometry {#sec4dot3-ijms-19-00761}
----------------------

Samples were measured in a randomized order. The LC-MS system consisted of an Ultimate 3000 (Dionex, Sunnyvale, CA, USA) nanoLC using an Acclaim PepMap 100 guard column with an Acclaim PepMap RSLC column (15 cm, 75 µM ID, both heated to 40 °C) and a QExactive (Thermo Scientific, Waltham, MA, USA) MS with a Nanospray Flex (ThermoFischer Scientific, Dreieich, Germany) source using steel emitters. The gradient used for the LC was as followed with the solvents A (*A. dest*, 0.1% acetic acid) and B (acetonitrile, 0.1% acetic acid): 0--4 min: 2% B, 4--65 min linear ramp to 35% B, 65--75 min linear ramp to 50% B, 75--80 min 50% B, 80--81 min linear ramp to 80% B, 81--85 min 80% B, 85--86 min linear ramp to 2% B, 86--100 min 2% B. Total flow was 300 nL/min. Calibration was performed on a daily basis using Pierce™ LTQ Velos ESI Positive Ion Calibration Solution (Thermo Scientific). QExactive measurements were conducted in positive mode in Full MS → dd-MS^2^ mode. For survey scans, 70,000 resolution in the range of 300 to 1650 *m*/*z* was used with an AGC target of 10^6^ and an ion time of 120 ms. For the Top10 MS/MS scans, a 17,500 resolution with an AGC target of 2 × 10^5^ and a stepped NCE of 27.5. Exclusion time for Top10 picking was 30 s, meaning that the 10 highest signals in a survey scan at any given time were fragmented and MS/MS spectra collected. Afterwards, these exact signals were ignored for determination of the highest signals for the next 30 s.

4.4. Data Analysis {#sec4dot4-ijms-19-00761}
------------------

Raw data were analyzed using Proteome Discoverer 2.0 (Thermo Scientific). All 10 gel slices from one lane, which were measured independently, were defined as fractions of a single experiment, resulting in four meta-samples. They were searched against the reviewed human proteome (Uniprot UP000005640) with a FDR of 0.01 (strict) and 0.05 (medium) for both peptides and PSMs. At least 2 unique peptides had to be present for strict annotation. For relative quantification, number of peptide spectral matches normalized by protein length, was used as given by the softwate (\#PSM). The following flexible modifications were included: carbamidomethylation at C, single oxidation at C & M, trioxidation at C & W, and nitration at Y. Carbamidomethylation was not set as a fixed modification as wound exposure to ambient conditions might result in oxidative modifications at cysteines. These modifications might not be properly reduced by DTT in the workflow. Results were tested against a mock-up database consisting of randomly generated peptides to determine the false discovery rate (FDR). Annotation procedure was attuned to keep FDR below the 0.05 (medium) and 0.01 (strict) thresholds. Additional information were retrieved using free online PANTHER analysis tools ([Figure 1](#ijms-19-00761-f001){ref-type="fig"}).

4.5. Analysis of Manually Collected Wound Material {#sec4dot5-ijms-19-00761}
--------------------------------------------------

To process cell pellets, the fixative was washed off, and cell were stained either with anti-myeloperoxidase (MPO) PE antibodies and 4′,6-diamidin-2-phenylindol (DAPI) to delineate DNA-MPO aggregates, or with antibodies targeted against anti-CD45 PE-Cy7, CD66b PerCP-Cy5.5, and CD16 PE-Dazzle (all BioLegend, San Diego, CA, USA). Cells were washed, and analyzed by multicolor flow cytometry (Beckman-Coulter, Brea, CA, USA). Supernatants obtained after centrifugation of swap material dissolved in PBS were investigated in several ways. To analyze microparticle and their origin, supernatant was centrifuged at 14,000× *g*, washed, stained with anti-CD15 APC (BioLegend) and bio-maleimide (BODIPY FL *N*-(2-Aminoethyl; Life Technologies, Carlsbad, CA, USA), washed, and analyzed by flow cytometry (Beckman-Coulter). Beads were utilized to set up the cytometer and to retrieve maximum sensitivity triggering over the side scatter as previously described \[[@B97-ijms-19-00761]\]. Flow analysis was performed with Kaluza software 1.5a (Beckman-Coulter). Graphs were made using prism 7.03 (Graphpad software). Sytox green (Thermo Scientific) was added supernatants, and the DNA concentration was quantified against a DNA standard curve (Thermo Scientific). Fluorescence was read using a microplate reader (Tecan, Männedorf, Switzerland) at λ~ex~ 485 nm and λ~em~ 535 nm. In a similar fashion, fluorescence of H~2~-DCF (Sigma, Taufkirchen, Germany) added the samples was determined to investigate presence of oxidants and oxidase activity.
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###### 

Apolipoproteins, glycoproteins, and protease inhibitors in wound fluids.

  Acronym    Protein Name   Acronym
  ---------- -------------- -------------------------------------------
  P08519     LPA            Apolipoprotein(a)
  P02647     APOA1          Apolipoprotein A-I
  P02652     APOA2          Apolipoprotein A-II
  P02656     APOC3          Apolipoprotein C-III
  P06727     APOA4          Apolipoprotein A-IV
  P04114     APOB           Apolipoprotein B-100
  P05090     APOD           Apolipoprotein D
  P02649     APOE           Apolipoprotein E
  O14791-3   APOL1          Isoform 3 of Apolipoprotein L1
  P04217     A1BG           Alpha-1B-glycoprotein
  P04217-2   A1BG-2         Isoform 2 of Alpha-1B-glycoprotein
  P02749     APOH           Beta-2-glycoprotein 1
  P13987     CD59           CD59 glycoprotein
  P04196     HRG            Histidine-rich glycoprotein
  P11279     LAMP1          Lysosome-associated membrane glycoprotein
  P02750     LRG1           Leucine-rich α-2-glycoprotein
  P02763     ORM1           Alpha-1-acid glycoprotein
  P02765     ORM2           Alpha-2-acid glycoprotein
  P25311     AZGP1          Zinc-α-2-glycoprotein
  P01009     SERPINA1       Alpha-1-antitrypsin
  P01009-2   SERPINA1-2     Isoform 2 of α-1-antitrypsin
  P01009-3   SERPINA1-3     Isoform 3 of α-1-antitrypsin
  P01011     SERPINA3       Alpha-1-antichymotrypsin
  P01011-2   SERPINA3-2     Isoform 2 of α-1-antichymotrypsin
  P05154     SERPINA5       Plasma serine protease inhibitor
  P08185     SERPINA6       Corticosteroid-binding globulin
  P35237     SERPB6         Serpin B6
  P05546     SERPIND1       Heparin cofactor 2
  P08670     SERPINF1       Pigment epithelium-derived factor
  P08697     SERPINF2       Alpha-2-antiplasmin
  P08697-2   SERPINF2-2     Isoform 2 of α-2-antiplasmin
  P00734     F2             Prothrombin
  P01008     SERPINC3       Antithrombin-III
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###### 

Complement components in wound fluids.

  Acronym    Protein Name   Acronym
  ---------- -------------- ------------------------------------------
  P01024     C3             Complement C3
  P0C0L5     C4B            Complement C4-B
  P01031     C5             Complement C5
  P13671     C6             Complement component C6
  P07360     C8G            Complement component C8 γ chain
  P02748     C9             Complement component C9
  P00751     CFB            Complement factor B
  P00751-2   CFB            Isoform 2 of Complement factor B
  P08603     CFH            Complement factor H
  P36980     CFHR2          Complement factor H-related protein 2
  P05156     CFI            Complement factor I
  Q9NZP8     C1RL           Complement C1r subcomponent-like protein
  P02746     C1QB           Complement C1q subcomponent subunit B
  P02747     C1QC           Complement C1q subcomponent subunit C
  P09871     C1S            Complement C1s subcomponent
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###### 

PTMs found in wound fluids (high confidence hits only).

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein ID   Acronym    Protein Name                                            PTMs ^a^
  ------------ ---------- ------------------------------------------------------- -------------------------------------------------------------------------
  P01834       IGKC       Immunoglobulin kappa constant                           Trioxidation \[C87\]

  P15814       IGLL1      Immunoglobulin lambda-like polypeptide 1                Trioxidation \[C194\];\
                                                                                  Oxidation \[M197\]

  Q04695       KRT17      Keratin, type I cytoskeletal 17                         Oxidation \[M88\]

  P30043       BLVRB      Flavin reductase (NADPH)                                Oxidation \[M87\];

  P02549       SPTA1      Spectrin α chain, erythrocytic 1                        Oxidation \[M647; M881\]

  P02549-2     SPTA1      Isoform 2 of Spectrin α chain, erythrocytic             Oxidation \[M647; M881\]

  P11142       HSPA8      Heat shock cognate 71 kDa protein                       Oxidation \[M61\]

  P0DMV9       HSPA1B     Heat shock 70 kDa protein 1B                            Oxidation \[M549\]

  P0DMV8-2     HSPA1A     Isoform 2 of Heat shock 70 kDa protein 1A               Oxidation \[M494\]

  Q14624       ITIH4      Inter-α-trypsin inhibitor heavy chain H4                Oxidation \[M491\]

  Q562R1       ACTBL2     Beta-actin-like protein 2                               Oxidation \[M45; M48; M191\];

  P26038       MSN        Moesin                                                  Oxidation \[M433; M451\]

  P12429       ANXA3      Annexin A3                                              Oxidation \[M40\]

  P01871       IGHM       Immunoglobulin heavy constant mu                        Oxidation \[M383\];

  P01871-2     IGHM       Isoform 2 of Immunoglobulin heavy constant mu           Oxidation \[M383\];

  P04004       VTN        Vitronectin                                             Oxidation \[M350\];

  P35542       SAA4       Serum amyloid A-4 protein                               Oxidation \[M35\]

  P30101       PDIA3      Protein disulfide-isomerase A3                          Oxidation \[M338\]

  P06727       APOA4      Apolipoprotein A-IV                                     Oxidation \[M322\]

  P30740       SERPINB1   Leukocyte elastase inhibitor                            Oxidation \[M307\]

  P04114       APOB       Apolipoprotein B-100                                    Oxidation \[M306; M3007; M3421\]

  P04264       KRT1       Keratin, type II cytoskeletal 1                         Oxidation \[M296\];

  P35237       SERPINB6   Serpin B6                                               Oxidation \[M291\]

  P40121       CAPG       Macrophage-capping protein                              Oxidation \[M261\]

  P02671       FGA        Fibrinogen α chain                                      Oxidation \[M259\]

  P02671-2     FGA        Isoform 2 of Fibrinogen α chain                         Oxidation \[M259\]

  P40121-2     CAPG       Isoform 2 of Macrophage-capping protein                 Oxidation \[M246\]

  P61981       YWHAG      14-3-3 protein γ                                        Oxidation \[M23; M27\]

  P02790       HPX        Hemopexin                                               Oxidation \[M229; M375; M409\];

  P47756-2     CAPZB      Isoform 2 of F-actin-capping protein subunit β          Oxidation \[M220\]

  Q06830       PRDX1      Peroxiredoxin-1                                         Oxidation \[M21\]

  P27105       STOM       Erythrocyte band 7 integral membrane protein            Oxidation \[M207; M228\]

  O15145       ARPC3      Actin-related protein 2/3 complex subunit 3             Oxidation \[M19\]

  P01860       IGHG3      Immunoglobulin heavy constant γ 3                       Oxidation \[M182; M288\];\
                                                                                  Trioxidation \[C27; C297\];

  P09525       ANXA4      Annexin A4                                              Oxidation \[M17\]

  P19823       ITIH2      Inter-α-trypsin inhibitor heavy chain H2                Oxidation \[M162\]

  P35527       KRT9       Keratin, type I cytoskeletal 9                          Oxidation \[M157; M234; M245; M269\]

  P08670       VIM        Vimentin                                                Oxidation \[M154\]

  P13645       KRT10      Keratin, type I cytoskeletal 10                         Oxidation \[M150\]

  P00915       CA1        Carbonic anhydrase 1                                    Oxidation \[M149; M242\]

  P01857       IGHG1      Immunoglobulin heavy constant γ 1                       Oxidation \[M135\];\
                                                                                  Trioxidation \[C27; C250\];\
                                                                                  Nitro \[Y161\]

  P01861       IGHG4      Immunoglobulin heavy constant γ 4                       Oxidation \[M132\];\
                                                                                  Trioxidation \[C247\];

  P01859       IGHG2      Immunoglobulin heavy constant γ 2                       Oxidation \[M131; M237\];\
                                                                                  Trioxidation \[C246\];

  P02787       TF         Serotransferrin                                         Oxidation \[M128; M332; C374\];\
                                                                                  Trioxidation \[C374\]

  P08779       KRT16      Keratin, type I cytoskeletal 16                         Oxidation \[M121\];

  P02533       KRT14      Keratin, type I cytoskeletal 14                         Oxidation \[M119\];

  P02647       APOA1      Apolipoprotein A-I                                      Oxidation \[M110; M136; M172\]

  P37837       TALDO1     Transaldolase                                           Oxidation \[M11\]

  P02679-2     FGG        Isoform γ-A of Fibrinogen γ chain                       Oxidation \[M104; M290\];

  P02679       FGG        Fibrinogen γ chain                                      Oxidation \[M104; M290\];

  P02792       FTL        Ferritin light chain                                    Oxidation \[M101\]

  A0M8Q6       IGLC7      Immunoglobulin lambda constant 7                        Oxidation \[C87\];\
                                                                                  Nitrosyl \[C87\];\
                                                                                  Nitro \[Y85\]

  A0A0C4DH72   IGKV1      Immunoglobulin kappa variable 1--6                      Oxidation \[C22; M26\]

  B9A064       IGLL5      Immunoglobulin lambda-like polypeptide 5                Oxidation \[C195\];\
                                                                                  Trioxidation \[C195\]

  P00450       CP         Ceruloplasmin                                           Nitro \[Y471\];\
                                                                                  Oxidation \[M538\]

  P68871       HBB        Hemoglobin subunit β                                    Nitro \[Y36\];\
                                                                                  Oxidation \[M56\];

  P02042       HBD        Hemoglobin subunit δ                                    Nitro \[Y36\]

  P00738       HP         Haptoglobin                                             Nitro \[Y280\];\
                                                                                  Oxidation \[M263; M300; M343\]

  P69905       HBA1       Hemoglobin subunit α                                    Nitro \[Y25\];\
                                                                                  Oxidation \[M33\]

  P00738-2     HP         Isoform 2 of Haptoglobin                                Nitro \[Y221\];\
                                                                                  Oxidation \[M204; M241; M284\]

  P01009       SERPINA1   Alpha-1-antitrypsin                                     Nitro \[Y184\];\
                                                                                  Oxidation \[M409\]

  P01009-3     SERPINA1   Isoform 3 of Alpha-1-antitrypsin                        Nitro \[Y184\]

  P01009-2     SERPINA1   Isoform 2 of Alpha-1-antitrypsin                        Nitro \[Y184\]

  P49913       CAMP       Cathelicidin antimicrobial peptide                      Nitro \[Y56\];\
                                                                                  Oxidation \[M109\]

  P02768       ALB        Serum albumin                                           Oxidation \[M111; C125; C289; M353; C500; C501; M572\];\
                                                                                  Trioxidation \[C125; C192; C224; C289; C302; C303; C500; C501; C591\];\
                                                                                  Nitro \[Y164; Y287\];\
                                                                                  Nitrosyl \[C289\]

  P02768-3     ALB        Isoform 3 of Serum albumin                              Oxidation \[M111; C125; C287; C288; M359\];\
                                                                                  Trioxidation \[C125; C287; C288; C378\]

  P02768-2     ALB        Isoform 2 of Serum albumin                              Oxidation \[C97; M161; C308; C309; M380\];\
                                                                                  Trioxidation \[C97; C110; C111; C308; C309; C399\];\
                                                                                  Nitro \[Y95\];\
                                                                                  Nitrosyl \[C97\]

  P0C0L5       C4B        Complement C4-B                                         Oxidation \[M393\]

  P01023       A2M        Alpha-2-macroglobulin                                   Oxidation \[M713; M1378\]

  P01024       C3         Complement C3                                           Oxidation \[M164; M495; M581; M990; M1347; M1384\]

  P08603       CFH        Complement factor H                                     Oxidation \[M1174\]

  P02788       LTF        Lactotransferrin                                        Oxidation \[C28; M411\];\
                                                                                  Trioxidation \[C28\]

  P02675       FGB        Fibrinogen β chain                                      Oxidation \[M254; M272\]

  P02788-2     LTF        Isoform δLf of Lactotransferrin                         Oxidation \[M367\]

  P02763       ORM1       Alpha-1-acid glycoprotein 1                             Nitro \[Y175\]

  P04406       GAPDH      Glyceraldehyde-3-phosphate dehydrogenase                Oxidation \[M328; M331\]

  P07738       BPGM       Bisphosphoglycerate mutase                              Oxidation \[M103\]

  P13796       LCP1       Plastin-2                                               Oxidation \[M166\]

  P04406-2     GAPDH      Isoform 2 of Glyceraldehyde-3-phosphate dehydrogenase   Oxidation \[M286; M289\]

  P07738       BPGM       Bisphosphoglycerate mutase                              Oxidation \[M103\]

  P13796       LCP1       Plastin-2                                               Oxidation \[M166\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Carbamidomethylations were excluded due to their introduction during sample preparation and their ubiquitous presence.

![Protein classification: (**a**) Molecular function; (**b**) cellular compartment; (**c**) biological process.](ijms-19-00761-g001){#ijms-19-00761-f001}

![Relative abundance of high confidence proteins as determined in the pooled wound fluid samples by liquid chromatography/mass spectrometry spectral counts.](ijms-19-00761-g002){#ijms-19-00761-f002}

![Flow cytometric analysis of cell pellets derived from manually removed wound material. (**a**) representative dot plot and (**b**) percent of CD16^+^/CD66b^+^ (neutrophils) and CD16^−^/CD66b^−^ cells among CD45^+^/DAPI^+^ cells; (**c**) pelleted material stained with DAPI only; (**d**) pelleted material stained against DAPI and MPO; (**e**) quantification of events staining positive for MPO and intermediate for DAPI. Data are from 6--8 patients.](ijms-19-00761-g003){#ijms-19-00761-f003}

![Supernatant analysis of manually removed wound material. (**a**) time of flight (TOF) gate in forward scatter (FS) height against FS TOF; (**b**) TOF gating analogous to (**a**); (**c**) size discrimination of small particles as predetermined with beads; (**d**) gate of membrane-positive particles as predetermined with unstained material; (**e**) discrimination between CD15^+^ and CD15^−^ microparticles as predetermined with unstained particles; (**f**) quantification CD15^+^ particles among all samples; (**g**) DNA content in supernatants as determined with sytox green against a known standard; (**h**) DCF fluorescence of wound material supernatant; data are one representative (**a**--**e**) or mean + S.E. of 8 (**f**), 3 (**g**), and 2 (**h**) samples.](ijms-19-00761-g004){#ijms-19-00761-f004}
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###### 

Patients enrolled in this study.

  Cohort Feature                               Value
  -------------------------------------------- ---------------------------------------------------------------------
  Number of Patients                           11
  Median patient age (years ± S.E.)            54 ± 4
  Sex (m/f)                                    9/2
  Wound type                                   11 trauma wounds (1 thoracic, 3 upper extremity, 7 lower extremity)
  Wound healing response                       11/11
  Median time to wound healing (days ± S.E.)   21 ± 4
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###### 

Oxidoreductases in wound fluids.

  Protein ID   Acronym   Protein Name                                     Protein Class
  ------------ --------- ------------------------------------------------ ----------------
  P04040       CAT       Catalase                                         Peroxidase
  Q06830       Prdx1     Peroxiredoxin 1                                  Peroxidase
  P32119       Prdx2     Peroxiredoxin 2                                  Peroxidase
  P30041       Prdx6     Peroxiredoxin 6                                  Peroxidase
  P05164-2     MPO       Isoform H14 of Myeloperoxidase                   Peroxidase
  P00441       SOD1      Superoxide dismutase 1                           Oxidoreductase
  P00403       MT-CO2    Cytochrome C oxidase 2                           Oxidoreductase
  P16083       NQO2      Ribosyldihydronicotinamide dehydrogenase         Oxidoreductase
  O95571       ETHE1     Persulfide dioxygenase                           Oxidoreductase
  P07195       LDHB      [l]{.smallcaps}-lactate dehydrogenase β          Dehydrogenase
  P40926       MDH2      Malate dehydrogenase 2                           Dehydrogenase
  P30043       BLVRB     Flavin reductase (NADPH)                         Reductase
  P20292       ALOX5AP   Arachidonate 5-lipoxygenase activating protein   Transferase
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###### 

Signaling and immune modulators, chaperones, and heat shock proteins in wound fluids. GDP: Guanosine-5′-triphosphate.

  Protein ID                            Acronym   Protein Name
  ------------------------------------- --------- ------------------------------------------------
  *Calmodulin-signaling molecules*                
  P26447                                S100A4    Protein S100 A4
  P06703                                S100A6    Protein S100 A6
  P05109                                S100A8    Protein S100 A8
  P06702                                S100A9    Protein S100 A9
  P31949                                S100A11   Protein S100 A11
  P25815                                S100P     Protein S100 P
  *Chaperone and heat shock proteins*             
  P31946                                YWHAB     14-3-3 protein β/α
  P61981                                YWHAG     14-3-3 protein γ
  P27348                                YWHAH     14-3-3 protein τ
  Q04917                                YWHAQ     14-3-3 protein ε
  P63104                                YWHAZ     14-3-3 protein ζ
  P27797                                CALR      calreticulin
  P14625                                HSP90B1   Endoplasmin
  P0DMV9                                HSPA1B    Heat shock 70 kDa protein 1B
  P11142                                HSPA8     Heat shock cognate 71 kDa protein
  P11142-2                              HSPA8     Isoform 2 of Heat shock cognate 71 kDa protein
  P0DMV8-2                              HSPA1A    Isoform 2 of Heat shock 70 kDa protein 1A
  *Immune modulators*                             
  P01023                                A2M       α2-macroglobulin
  P43490                                NAMPT     Nicotinamide phosphoribosyltransferase
  P52565                                ARHGD     Rho GDP-dissociation inhibitor 1
  P52566                                ARHGD     Rho GDP-dissociation inhibitor 2
  P04083                                ANXA1     Annexin A1
  P07355                                ANXA2     Annexin A2
  P12429                                ANXA3     Annexin A3
  P09525                                ANXA4     Annexin A4
  P09525-2                              ANXA4     Annexin A4 Isoform 2
  P08758                                ANXA5     Annexin A5
  P50995                                ANXA11    Annexin A11
  P50995-2                              ANXA11    Annexin A11 Isoform 2
  P20292                                ALOX5AP   Arachidonate 5-lipoxygenase activating protein
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###### 

Neutrophil- and leukocyte-associated factors in wound fluids.

  Protein ID   Acronym      Protein Name
  ------------ ------------ ---------------------------------------------------------
  P20160       AZU1         Azurocidin
  P02788       LTF          Lactotransferrin
  P02788-2     LTF          Isoform δLf of Lactotransferrin
  P17213       BPI          Bactericidal permeability-increasing protein
  P08311       CTSG         Cathepsin G
  Q9UBR2       CTSZ         Cathepsin Z
  P00747       PLG          Plasminogen
  P61626       LYZ          Lysozyme
  P08246       ELANE        Neutrophil elastase
  P30740       SERPINB1     Leukocyte elastase inhibitor
  P30740-2     SERPINB1-2   Leukocyte elastase inhibitor isoform 2
  P80188       LCN2         Neutrophil gelatinase-associated lipocalin
  P80188-2     LCN2         Isoform 2 of Neutrophil gelatinase-associated lipocalin
  Q15582       TGFB1        Transforming growth factor B1
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###### 

Extracellular matrix proteins in wound fluids.

  Protein ID   Acronym   Protein Name
  ------------ --------- ---------------------------------------
  P02671       FGA       Fibrinogen α chain
  P02675       FGB       Fibrinogen β chain
  P02679       FGG       Fibrinogen γ chain
  P02671-2     FGA2      Isoform 2 of Fibrinogen α chain
  P02679-2     FGGA      Isoform γ A of Fibrinogen γ chain
  P02452       COL1A1    Collagen α-1(I) chain
  P08123       COL1A2    Collagen α-2(I) chain
  P20908       COL5A1    Collagen α-1(V) chain
  P12109       COL6A1    Collagen α-1(VI) chain
  O00602       FCN-1     Ficolin 1
  P51884       LUM       Lumican
  P04004       VTN       Vitronectin
  Q6UX06       OLFM4     Olfactomedin-4
  P49747-2     COMP2     Cartilage oligomeric matrix protein 2
  P17931       LGALS3    Galectin 3
  P50552       VASP      Vasodilator-stimulated phosphoprotein
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###### 

Proteinases and peptidases in wound fluids.

  Protein ID   Acronym   Protein Name
  ------------ --------- ------------------------------------------
  P13798       ACPH      Acylamino-acid-releasing enzyme
  P15144       AMPN      Aminopeptidase N
  P15169       CBPN      Carboxypeptidase N catalytic chain
  P42574       CASP3     Caspase-3
  P08311       CATG      Cathepsin G
  Q9UBR2       CATZ      Cathepsin Z
  Q9NZP8       C1RL      Complement C1r subcomponent-like protein
  P09871       C1S       Complement C1s subcomponent
  P00751       CFAB      Complement factor B
  P05156       CFAI      Complement factor I
  P02788       TRFL      Lactotransferrin
  P14780       MMP9      Matrix metalloproteinase-9
  P24158       PRTN3     Myeloblastin
  P08246       ELNE      Neutrophil elastase
  P00747       PLMN      Plasminogen
  P25789       PSA4      Proteasome subunit α type-4
  P28066       PSA5      Proteasome subunit α type-5
  P20618       PSB1      Proteasome subunit β type-1
  P40306       PSB10     Proteasome subunit β type-10
  P28070       PSB4      Proteasome subunit β type-4
  P28072       PSB6      Proteasome subunit β type-6
  Q99436       PSB7      Proteasome subunit β type-7
  P00734       THRB      Prothrombin
